TABLE 4.

Predictors of Completion of the HPV4 Vaccination Series Within 7 and 12 Months: Results of Multivariable Logistic Regression

	Vaccine-Completion Period
	7 mo		12 mo
	Adjusted OR	95% CI	Adjusted OR	95% CI
Race
White vs black	2.04	1.64–2.56a	1.92	1.59–2.27a
White vs otherb	1.35	0.83–2.22	1.45	0.96–2.22
Insurance
Private vs public	1.31	1.06–1.63c	1.16	0.97–1.38
Public vs none	1.47	0.69–3.13	2.08	1.16–3.70c
DMPA any timed	1.53	1.21–1.95a	2.06	1.72–2.47a
Time since vaccine available, moe	0.96f	0.94–0.98a	0.98f	0.96–0.99g

OR indicates odds ratio; CI, confidence interval; DMPA, depot medroxyprogesterone acetate.

^aP < .001.

^bIncludes Asian, mixed race, American Indian, and other.

^cP < .05.

^dReceipt of depot medroxyprogesterone acetate at any time during the vaccine-completion period.

^eMonths since November 2006.

^fOdds reported for each 1-month period since first dose given at Cincinnati Children's Hospital Medical Center.

^gP < .01.